Details

Autor(en) / Beteiligte

• Suzuki, Sho
• Tominaga, Naoyuki
• Aoki, Tomonori
• Sadashima, Eiji
• Miike, Tadashi
• Kawakami, Hiroshi
• Kobayashi, Katsumasa
• Yamauchi, Atsushi
• Yamada, Atsuo
• Omori, Jun
• Ikeya, Takashi
• Aoyama, Taiki
• Sato, Yoshinori
• Kishino, Takaaki
• Ishii, Naoki
• Sawada, Tsunaki
• Murata, Masaki
• Takao, Akinari
• Mizukami, Kazuhiro
• Kinjo, Ken
• Fujimori, Shunji
• Uotani, Takahiro
• Fujita, Minoru
• Sato, Hiroki
• Narasaka, Toshiaki
• Hayasaka, Junnosuke
• Funabiki, Tomohiro
• Kinjo, Yuzuru
• Mizuki, Akira
• Kiyotoki, Shu
• Mikami, Tatsuya
• Gushima, Ryosuke
• Fujii, Hiroyuki
• Fuyuno, Yuta
• Hikichi, Takuto
• Toya, Yosuke
• Narimatsu, Kazuyuki
• Manabe, Noriaki
• Nagaike, Koji
• Kinjo, Tetsu
• Sumida, Yorinobu
• Funakoshi, Sadahiro
• Kobayashi, Kiyonori
• Matsuhashi, Tamotsu
• Komaki, Yuga
• Kaise, Mitsuru
• Nagata, Naoyoshi

Titel

Association of blood group O with a recurrent risk for acute lower gastrointestinal bleeding from a multicenter cohort study

Ist Teil von

• Scientific reports, 2024-06, Vol.14 (1), p.13983-9

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• The relationship between blood group and rebleeding in acute lower gastrointestinal bleeding (ALGIB) remains unclear. This study aimed to investigate the association between blood group O and clinical outcomes in patients with ALGIB. The study included 2336 patients with ALGIB whose bleeding source was identified during initial endoscopy (from the CODE BLUE-J Study). The assessed outcomes encompassed rebleeding and other clinical parameters. The rebleeding rates within 30 days in patients with blood group O and those without blood group O were 17.9% and 14.9%, respectively. Similarly, the rates within 1 year were 21.9% for patients with blood group O and 18.2% for those without blood group O. In a multivariate analysis using age, sex, vital signs at presentation, blood test findings, comorbidities, antithrombotic medication, active bleeding, and type of endoscopic treatment as covariates, patients with blood group O exhibited significantly higher risks for rebleeding within 30 days (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.04–1.65; P  = 0.024) and 1 year (OR 1.29; 95% CI 1.04–1.61; P  = 0.020) compared to those without blood group O. However, the thrombosis and mortality rates did not differ significantly between blood group O and non-O patients. In patients with ALGIB, blood group O has been identified as an independent risk factor for both short- and long-term rebleeding.